Raising testosterone without testosterone
Testosterone therapy replaces the hormone and switches off the system that makes it. Three other drugs work the opposite way, releasing a brake so that a man’s own testes resume production.
Three drugs are used to raise testosterone without giving testosterone: letrozole, an aromatase inhibitor, and the selective estrogen receptor modulators clomiphene and enclomiphene. All three act on the hypothalamic-pituitary-testicular axis — the chain of signals running from the brain to the testes — rather than bypassing it, so the pituitary’s LH signal rises and the testes resume production instead of being silenced. In our practice letrozole is used more often than either clomiphene or enclomiphene: it addresses the specific problem that the commonest presentation of low testosterone turns on, and it is inexpensive. The evidence behind all three is narrower than the mechanism suggests, and the limits are set out below.
The problem letrozole addresses
Fat tissue produces aromatase, the enzyme that converts testosterone into estradiol. In a man carrying a large amount of visceral fat, more of his testosterone is shunted down that route and estradiol rises, and estradiol is a potent suppressor of the pituitary’s LH signal. Less LH means less stimulation of the testes, which means less testosterone, which means a smaller pool to start from the next time round.
The blood picture is characteristic: a low testosterone, an estradiol that is high or at any rate not low, and an LH that is low or inappropriately normal rather than elevated. The testes of such a man are capable of producing testosterone and are not being asked to.
Giving that man exogenous testosterone replaces the output and silences the signal for as long as he takes it. Blocking aromatase instead curbs the shunting of testosterone to estrogen, so estradiol falls, LH rises, and his own production returns.
What letrozole does to the hormones
The hormonal effect is reproducible and the figures are not in dispute. In twelve obese men with low free testosterone, letrozole 2.5 mg once weekly moved estradiol from 123 to 58 pmol/L, LH from 4.4 to 11.1 U/L, and total testosterone from 5.9 to 19.6 nmol/L, normalising the level in every man in the study, with levels stable across the week and across six months. An earlier pilot in ten severely obese men, at higher weekly doses, moved total testosterone from 7.5 to 23.8 nmol/L and normalised all ten.
| Study | Men | Total testosterone | Estradiol | LH |
|---|---|---|---|---|
| Letrozole 2.5 mg weekly, six months | 12 obese men | 5.9 → 19.6 nmol/L | 123 → 58 pmol/L | 4.4 → 11.1 U/L |
| Letrozole pilot, higher weekly doses | 10 severely obese men | 7.5 → 23.8 nmol/L | — | — |
| Letrozole, placebo-controlled, six months | 42 obese men | 8.6 → 21.5 nmol/L | — | — |
One finding from the first of those studies bears directly on dosing: free testosterone went supraphysiological in 7 of the 12 men at 2.5 mg once weekly. The dose used for this purpose is accordingly lower than the dose the drug carries in oncology, where it originated, and it is chosen for the individual man rather than taken from a standard schedule.
Where the evidence stops
The only double-blind, placebo-controlled letrozole trial in these men — 42 obese men with low testosterone, over six months — raised total testosterone from 8.6 to 21.5 nmol/L and found no significant effect on any prespecified endpoint: psychological function, body composition, exercise capacity, glucose, lipids or bone metabolism. The authors’ conclusion was that despite a marked rise in serum testosterone, low-dose aromatase inhibition had no somatic or psychological effects.
A parallel randomised trial of anastrozole alongside a weight-loss programme, in 23 men, found higher testosterone and greater fat loss on the drug, but no difference in hypogonadal symptoms or muscle strength compared with weight loss alone.
What exists is therefore a reproducible and mechanistically coherent hormonal effect, in a well-defined group of men, without a demonstrated effect on how those men feel or function. Total randomised exposure across the entire letrozole literature is well under 150 men, all of it at six months or less and almost all of it from two centres. The clinical benefit remains unestablished, and a claim that it has been established goes beyond what the trials report.
The bone question is the limiting one
Estradiol rather than testosterone is the dominant regulator of male skeletal health, so a drug whose mechanism is lowering estradiol carries an obvious liability, and that liability has been measured. In a one-year randomised trial of anastrozole in 69 men aged 60 and over, testosterone rose from 319 to 524 ng/dL, estradiol fell from 15 to 12 pg/mL, and spine bone density fell on the drug while it rose on placebo. The authors concluded that aromatase inhibition does not improve skeletal health in ageing men.
Two features make that result less directly applicable to a younger obese man, and neither of them settles the question. Those men were older and started with estradiol in the normal range, so there was little margin to give up, whereas an obese man whose baseline estradiol is markedly elevated is plausibly in a different position; and a six-month pilot in 23 obese men found no skeletal signal, in a sample too small to reassure. No long-term bone data exist in the obese population at all, which makes the favourable trade-off plausible rather than demonstrated. Bone density therefore belongs in the discussion before treatment starts and in the follow-up afterwards.
Clomiphene and enclomiphene
Selective estrogen receptor modulators reach the same destination by a different route. Rather than preventing estradiol from being made, they block its feedback signal at the pituitary; LH rises, testosterone follows, and because the axis is being driven rather than bypassed, sperm production is preserved.
Enclomiphene is the purified active isomer of clomiphene, and its randomised data are reasonable. In two phase III trials in overweight men with secondary hypogonadism, it raised testosterone, LH and FSH while maintaining sperm concentration in the normal range, whereas testosterone gel raised testosterone but produced a marked reduction in spermatogenesis.
Two further facts belong beside those results. Enclomiphene was never approved by the FDA: the application drew a Complete Response Letter in late 2015 and no approval has followed, so every prescription in the United States is a compounded product with no FDA-reviewed label. And on clomiphene, the Endocrine Society guideline states that neither its efficacy nor its safety has been demonstrated in randomised trials.
No adequately powered head-to-head trial compares letrozole with clomiphene or enclomiphene using testosterone as the endpoint. Any ranking of the three therefore rests on mechanism and clinical experience rather than on a comparison that has been performed.
Where the guidelines sit
The guidelines permit these drugs without endorsing them. The AUA’s statement on aromatase inhibitors, human chorionic gonadotropin and selective estrogen receptor modulators is a conditional recommendation at evidence level C, and it is confined to men who wish to maintain fertility rather than extending to the general treatment of low testosterone. The Endocrine Society does not grade aromatase inhibitors at all.
These are off-label treatments. In our practice, used in the right man and for the right reason, they are frequently the better choice than testosterone, and letrozole is the one used most often of the three — the obese man with a raised estradiol and an unelevated LH is the commonest presentation, the mechanism matches the problem in front of him, and the drug is cheap. That is a clinical judgement rather than a guideline position.
The man this suits
The phenotype is usually straightforward to recognise: obese or carrying substantial visceral fat, with a low testosterone, an estradiol that is not low, an LH that is not elevated, and either a wish to preserve fertility or a reluctance to commit to lifelong therapy. He is often in his thirties or forties, and often nobody has mentioned that anything exists between doing nothing and starting injections.
The aromatase problem is downstream of the adiposity and the drug does not treat the adiposity, so the upstream causes — weight, sleep apnoea, alcohol and sleep — are addressed alongside treatment rather than instead of it. Two further distinctions shape how these drugs are used: the hormone that is followed is estradiol as much as testosterone, because the entire mechanism runs through estradiol, and the limiting consideration over time is bone rather than the testosterone level.
Which of these drugs fits a given man, at what dose, and with what laboratory follow-up are worked out individually at the practice, and they are not reducible to a schedule that can be followed from a web page.
Questions patients ask
Letrozole raises testosterone, so it will make me feel the way testosterone does.
It raises the level reliably; whether it changes how a man feels has not been shown.
What the evidence showsThe only placebo-controlled letrozole trial in obese hypogonadal men — 42 men over six months — raised total testosterone from 8.6 to 21.5 nmol/L and found no significant effect on psychological function, body composition, exercise capacity, glucose, lipids or bone. A randomised anastrozole trial alongside weight loss found no difference in symptoms or strength compared with weight loss alone.
What remains uncertainWhether a longer trial, a different endpoint or a better-selected population would show benefit. Total randomised exposure is under 150 men, at six months or less.
Bottom lineA rational intervention with hormonal evidence behind it and an outcome literature that is so far empty, which is worth knowing before starting.
Mixed — Strong on hormones, Unsupported on outcomes
Since it isn’t testosterone, it must be the safer option.
It is safer for fertility, and bone is the open question.
What the evidence showsBecause aromatase inhibitors and SERMs work through the axis rather than around it, LH and FSH rise and sperm production is preserved, the opposite of exogenous testosterone, which suppresses both. But estradiol is the dominant regulator of male bone, and in a one-year randomised trial of anastrozole in 69 men aged 60 and over, spine bone density fell on the drug and rose on placebo while testosterone rose from 319 to 524 ng/dL.
What remains uncertainWhether that bone finding applies to a younger obese man whose baseline estradiol is high. A six-month pilot in 23 obese men found no signal, and no long-term data exist in that population.
Bottom lineA different risk profile rather than an absent one, with bone part of the discussion before treatment begins.
Moderate
Enclomiphene is the modern, approved version of clomiphene.
It is the purified isomer, and it is not approved.
What the evidence showsTwo phase III trials showed enclomiphene raising testosterone, LH and FSH while maintaining sperm concentration in the normal range, where testosterone gel markedly reduced spermatogenesis. The FDA issued a Complete Response Letter in late 2015 and no approval followed, so prescriptions in the United States are compounded products without an FDA-reviewed label.
What remains uncertainWhether it would be approved on a modern trial programme, which nobody has run.
Bottom lineReasonable randomised data, a real sperm-preserving advantage, and no FDA approval; all three are true at once.
Moderate
My doctor should simply pick whichever of these works best.
No trial exists that would allow anyone to do that.
What the evidence showsThere is no adequately powered head-to-head trial of letrozole against clomiphene or enclomiphene with testosterone as the primary endpoint. The only quantitative comparison is an indirect network meta-analysis rated low quality, which used semen parameters rather than testosterone and concluded that there is insufficient evidence to support routine use of any of them.
What remains uncertainEssentially the whole comparative question.
Bottom lineThe choice is made on phenotype, fertility plans, estradiol level and tolerability, which is a clinical judgement rather than a trial result.
Limited
If letrozole fixes my testosterone, I don’t need to lose the weight.
The drug acts on a consequence of the excess fat, not on the fat itself.
What the evidence showsAromatase comes from fat tissue, so the low testosterone in this phenotype is downstream of the adiposity, and letrozole leaves the adiposity in place. In the placebo-controlled trial of 42 obese men, body composition and metabolic endpoints did not change despite total testosterone rising from 8.6 to 21.5 nmol/L. In the anastrozole trial, the men who lost more fat were doing so on a weight-loss programme, and their symptoms and strength were no better than those on the programme alone.
What remains uncertainHow far weight loss alone would restore testosterone in the same men, since no trial has compared the two directly over a long period.
Bottom lineTreating the cause and raising the hormone are separate objectives, and the drug addresses only the second.
Limited
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
Our endocrinologists evaluate low testosterone in La Jolla, La Mesa and Poway: low testosterone care at Diabetes & Endocrine Specialists.


